[
    [
        {
            "time": "2021-03-26",
            "original_text": "睿智医药：客户类型涵盖大型制药企业、生物科技公司及科研院校",
            "features": {
                "keywords": [
                    "睿智医药",
                    "客户类型",
                    "制药企业",
                    "生物科技公司",
                    "科研院校"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "睿智医药：客户类型涵盖大型制药企业、生物科技公司及科研院校",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-26",
            "original_text": "恒瑞「卡瑞利珠单抗」新适应症申报上市，预计为一线治疗鳞状NSCLC和食管癌",
            "features": {
                "keywords": [
                    "恒瑞",
                    "卡瑞利珠单抗",
                    "新适应症",
                    "鳞状NSCLC",
                    "食管癌"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞「卡瑞利珠单抗」新适应症申报上市，预计为一线治疗鳞状NSCLC和食管癌",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-03-26",
            "original_text": "江苏区域股市周报：总市值跌573亿8133万融资买入长电科技",
            "features": {
                "keywords": [
                    "江苏",
                    "股市周报",
                    "总市值",
                    "长电科技"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "电子",
                    "半导体"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "江苏区域股市周报：总市值跌573亿8133万融资买入长电科技",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-26",
            "original_text": "「最惨」新基金成立仅半年巨亏超30%，同期指数大涨8%",
            "features": {
                "keywords": [
                    "新基金",
                    "巨亏",
                    "指数",
                    "大涨"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "基金"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "「最惨」新基金成立仅半年巨亏超30%，同期指数大涨8%",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-26",
            "original_text": "近150亿资金杀向抱团股，抢筹名单来了！",
            "features": {
                "keywords": [
                    "资金",
                    "抱团股",
                    "抢筹"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "股票市场"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "近150亿资金杀向抱团股，抢筹名单来了！",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-03-26",
            "original_text": "恒瑞医药（600276.SH）：贝伐珠单抗注射液及SHR-1701注射液获批临床试验",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "贝伐珠单抗",
                    "SHR-1701",
                    "临床试验"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药（600276.SH）：贝伐珠单抗注射液及SHR-1701注射液获批临床试验",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-03-26",
            "original_text": "高瓴资本概念股近三日最受主力资金青睐",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "主力资金",
                    "概念股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "投资",
                    "资本"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴资本概念股近三日最受主力资金青睐",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-26",
            "original_text": "创新药的另类尴尬：打破头进医保，却依然卖不动",
            "features": {
                "keywords": [
                    "创新药",
                    "医保",
                    "销售"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "政策"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "创新药的另类尴尬：打破头进医保，却依然卖不动",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-26",
            "original_text": "蓝帆医疗商誉减值17.6亿；多家药企公布业绩，先声药业利润下滑34%",
            "features": {
                "keywords": [
                    "蓝帆医疗",
                    "商誉减值",
                    "药企",
                    "先声药业",
                    "利润下滑"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "财务"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "蓝帆医疗商誉减值17.6亿；多家药企公布业绩，先声药业利润下滑34%",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-03-26",
            "original_text": "A股融资融券日报：两融余额减少40.24亿元（3月25日）",
            "features": {
                "keywords": [
                    "A股",
                    "融资融券",
                    "两融余额",
                    "减少"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "股票市场",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额减少40.24亿元（3月25日）",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 10
            }
        }
    ]
]